FY 25 Revenues at INR 2,894 Crore, up 44% YoY

FY 25 EBITDA at INR 1,017 Crore, up 51% YoY, with 35% EBITDA margin

FY 25 PAT stood at INR 375 Crore, with 13% PAT margin

Mumbai, May 19, 2025: Eris Lifesciences Limited, a leading Indian branded formulations manufacturing company, today announced its earnings for the fourth quarter and full year FY25.

Consolidated Financial Highlights:

Particulars  (INR crore)	Q4FY25	Q4FY24	YoY(%)	FY25	FY24	YoY(%)
Revenue	705	551	28.0%	2,894	2,009	44.0%
Gross Profit	535	433	23.6%	2,180	1,629	33.8%
EBITDA	252	148	70.0%	1,017	675	50.7%
EBITDA Margin	35.8%	26.9%	886 bps	35.2%	33.6%	161 bps
PAT	102	80	28.3%	375	397	-5.7%
PAT Margin	14.5%	14.5%	0 bps	12.9%	19.8%	-687 bps

Commenting on the results, Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd., said, “Our Branded Formulations business has delivered a 10% organic growth in Q4. Our Diabesity strategy is progressing in line with our expectations and we have created an exciting pipeline in Insulins, Analogues and GLPs. We will take the lead in ensuring continued supply of life-saving insulins to patients across the country following the impending exit of the innovator from the RHI Penfill market. With our FY23 and FY24 investments fully integrated and growth-ready, we look forward to an exciting phase of secular growth over the next 3 years.”

Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer added, “We have realised significant operating margin improvements in our DBF business due to synergies from business integration and rapid progress in insourcing of manufacturing, including the start of insulin production from our Bhopal facility. We have made significant investments in Swiss Parenterals to create new revenue streams, the full potential of which will start getting realised from FY27. We are entering a 3-year period of secular organic growth with significant inflection expected in our EPS and ROCE trajectories.”

Q4FY25 and FY25 – Financial Highlights

• Revenue of Q4 FY 25 grew by 28% YoY to INR 705 Cr and FY 25 grew by 44% YoY to INR 2,894 Cr
• EBITDA for Q4 FY 25 is INR 252 Cr, with 36% EBITDA margin and FY 25 is INR 1,017 Cr with 35% EBITDA margin
• PAT for Q4 FY 25 is INR 102 Cr with 14% PAT margin and FY 25 is INR 375 Cr with 13% PAT margin
• Operating Cash flows are 111% of EBITDA in Q4 and 105% of EBITDA in FY 25
• Net Debt as on 31 March is ~INR 2,222 Cr

FY25 – Business Highlights

• Organic Domestic Branded Formulations business grew by 9% yoy
• Domestic Branded Formulations segment revenue grew by 32% yoy and EBITDA margin grew by 207 bps
• 15 out of Top-25 mother brands ranks among Top-5 in their respective markets with revenues of 5 mother brands above INR 100 Crs.

About Eris Lifesciences Ltd (BSE: 540596, NSE: ERIS):

Established in 2007, Eris is the youngest among the Top-20 pharma companies in India. With an annual branded formulations revenue of INR 3,000+ crore as per AWACS, Eris has built a diversified presence across specialties and super-specialties such as Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women’s Health, Oncology and Critical Care. Eris manufactures a wide range of prescription products across several dosage forms including oral solids, oral liquids, softgels, ointments, sprays & gels, sterile injectables and biologics in its 6 manufacturing facilities, and markets these products across India through a network of 2,000+ stockists and 5,00,000+ retail pharmacies.

Eris’ revenue and operating profit have grown 2.6x in the last 5 years, with FY 25 revenue of INR 2,894 cr. The company has diversified its presence across geographies, technologies and therapeutic areas with an investment of ~ INR 4,000 crore over the last 3 years. 

For further details please contact

Company

Eris Lifesciences Limited    CIN No: L24232GJ2007PLC049867 Kruti Raval                                                                              Email Id: kruti@erislifesciences.com

Safe Harbor

This document includes forward-looking information and statements including statements concerning the outlook for our businesses. These statements are based on current expectations, estimates and projections that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. 

These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, allocations of funds by the Governments in the healthcare sector, increasing competition and the conditions of our customers, suppliers and the pharmaceutical industry, global and Indian demand-supply conditions finished goods prices, cyclical demand and pricing in the company’s principal markets, changes in government laws and regulations, tax regimes, our provisioning policies, economic and political developments within India and the countries within which the company conducts businesses and other factors such as litigation and labour negotiations. 

Any forward-looking statement or information contained in this document speaks only as of the date of the statement. 

The company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events or otherwise unless it is required by Law.